Dapagliflozin for Cardio-renal Protection After ICU Discharge
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT07025629
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Registry
-
NCT07025629
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT07025629. Randomized; double masking; primary purpose treatment. Start 2025-12-02 (actual); primary completion 2029-01-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin for Cardio-renal Protection After ICU Discharge
- Acronym
- DAPA-ICU
- Condition
- Heart Failure and Chronic Kidney Disease Post-ICU
- Intervention (Drug)
- Dapagliflozin 10 MG Oral Tablet [Farxiga]
- Intervention (Drug)
- One tablet of placebo of dapagliflozin 10 mg
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct07025629- Content hash
09dcb08d4b31a161fdc3b12ef1cdd08aee0d7ac951059cc416e5fe04387f4319